Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

被引：54

作者：

Mizuno, Y

Yanagisawa, N

Kuno, S

Yamamoto, M

Hasegawa, K

Origasa, H

Kowa, H

机构：

[1] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan

[2] Kanto Rosai Hosp, Kawasaki, Kanagawa, Japan

[3] Natl Utano Hosp, Ctr Neurol Dis, Clin Res Sect, Kyoto, Japan

[4] Kagawa Prefectural Cent Hosp, Dept Neurol, Takamatsu, Kagawa, Japan

[5] Sagamihara Natl Hosp, Dept Neurol, Sagamihara, Kanagawa, Japan

[6] Toyama Med & Pharmaceut Univ, Fac Med, Div Biostat, Toyama, Japan

[7] Kitasato Univ, Tokyo, Japan

来源：

MOVEMENT DISORDERS | 2003年 / 18卷 / 10期

关键词：

Parkinson's disease; pramipexole; bromocriptine; levodopa; drug comparison; randomized controlled trial (RCT);

D O I：

10.1002/mds.10508

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (1311) group was included to enable determination of the noninferiority of PPX relative to 1311 as the standard treatment. (C) 2003 Movement Disorder Society.

引用

页码：1149 / 1156

页数：8

共 26 条

[1] The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, crossover study [J].

Boas, J ;

WormPetersen, J ;

Dupont, E ;

Mikkelsen, B ;

Wermuth, L .

EUROPEAN JOURNAL OF NEUROLOGY, 1996, 3 (01) :44-49

[2]

BRUNT E, 1996, J NEUROL, V243, pS38

[3] CRITERIA FOR DIAGNOSING PARKINSONS-DISEASE [J].

CALNE, DB ;

SNOW, BJ ;

LEE, C .

ANNALS OF NEUROLOGY, 1992, 32 :S125-S127

[4]

Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556

[5]

Fahn S, 1987, RECENT DEV PARKINSON, p[293, 153]

[6] Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole [J].

Frucht, S ;

Rogers, JD ;

Greene, PE ;

Gordon, MF ;

Fahn, S .

NEUROLOGY, 1999, 52 (09) :1908-1910

[7]

Frucht SJ, 1999, NEUROLOGY, V52, pA409

[8] Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease [J].

Guttman, M ;

Ott, E ;

Tragner, H ;

Bedard, PJ ;

Pourcher, E ;

Curran, T ;

Goodridge, A ;

Guttman, M ;

Hobson, D ;

King, D ;

Martin, WRW ;

Mendis, T ;

Rajput, A ;

Rivest, J ;

Stoessl, J ;

Suchowersky, O ;

Moran, J ;

Murphy, R ;

Walsh, B ;

ONeill, DO ;

Klemperer, B ;

Martin, M ;

Oehlwein, C ;

Polzer, U ;

Reichmann, H ;

Schimek, J ;

Schlenker, M ;

Schwartz, A ;

Meier, D ;

Traubner, P ;

Benetin, J ;

Bomhof, MAM ;

Hovestadt, A ;

Vreeling, FW ;

Wolters, ECMJ ;

Broddie, HG ;

Clarke, C ;

Clough, CJ ;

Loizou, L ;

Newman, PK ;

Pye, IF .

NEUROLOGY, 1997, 49 (04) :1060-1065

[9] Ropinirole and pramipexole, the new agonists [J].

Hobson, DE ;

Pourcher, E ;

Martin, WRW .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 26 :S27-S33

[10] Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations [J].

Inzelberg, R ;

Nisipeanu, P ;

Rabey, JM ;

Orlov, E ;

Catz, T ;

Kippervasser, S ;

Schechtman, E ;

Korczyn, AD .

NEUROLOGY, 1996, 47 (03) :785-788

← 1 2 3 →